This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Tryptophan, Serotonin and Kynurenine in Septic Shock (TSK)

This study has been completed.
Information provided by:
Versailles Hospital Identifier:
First received: May 22, 2008
Last updated: August 7, 2008
Last verified: May 2008
Septic shock is a major cause of mortality and morbidity worldwide. Serotonin (5-HT) is released by activated platelets into the circulation, and is mediator of endothelial dysfunction. 5-HT metabolism is known in immune system via specific 5-HT receptor, also in effects on the peripheral nervous system. Kinetic of 5-HT, tryptophan, kynurenine, MAO activity and IDO activity in human septic shock was never investigated.

Shock, Septic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Tryptophan, Serotonin and Kynurenine in Septic Shock

Resource links provided by NLM:

Further study details as provided by Versailles Hospital:

Primary Outcome Measures:
  • Kinetics of 5-HT, 5-HIAA, kynurenine, tryptophan, HVA, VMA, DOPAC, Oestradiol, Cotinine and vasopressors [ Time Frame: Day-1, Day-2, Day-3, Day-7 and Day-14 ]

Secondary Outcome Measures:
  • Mortality [ Time Frame: 28-day ]

Enrollment: 30
Study Start Date: June 2004
Study Completion Date: April 2008
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients who were 18 years of age or older and had been hospitalized in our ICU were prospectively enrolled in the study if they met all eligibility criteria. Inclusion criteria were clinical evidence of infection, evidence of a systemic response to infection, and the onset of shock within the previous 3 hours.

Inclusion Criteria:

  • Age above or equal to 18 years
  • Strong presumption clinical sepsis
  • Need for mechanical ventilation
  • Body temperature above 38°C or below 36°C
  • Heart rate above 90 bpm
  • Systolic blood pressure of <90mm Hg despite adequate fluid replacement or a need for vasopressors less than 3 hours
  • Presence of at least one of the following criteria:

    • Ratio of arterial oxygen tension over inspired fraction of oxygen of less than 300 mm Hg
    • Urinary output below 0.5 mL per kg of bodyweight per h or below 30 mL/h (for at least 1 h)
    • Arterial lactate concentration above 2 mmol/L
  • Consent signed

Exclusion Criteria:

  • Age below 18 years
  • Pregnancy
  • Underlying disease with a poor prognosis, a life expectancy of less than 24 hours
  • Depression or melancholy
  • Neuropsychiatric diseases: Seizure, manic psychosis, Migraine, or Drug addiction
  • Neuroendocrine tumors
  • Obstructive cardiomyopathy or acute myocardial ischaemia
  • Pulmonary embolism
  • Advanced stage cancer, malignant haemopathy, or AIDS with a decision to withhold or withdraw aggressive therapies
  • Inclusion in another clinical trial
  • Patient who receive before inclusion one of the following treatment known to modify serotonin level: almotriptan, amitriptyline, amoxapine, citalopram, clomipramine, clozapine, desipramine, dihydroergotamine, dolasetron, dosulepin, doxepin, eletriptan, ergotamine, flunarizine, fluoxetine, fluvoxamine, granisetron, imipramine, indoramin, interferon Alfa, interferon alfacon-1, interferon beta, iproniazid, maprotiline, methysergide, mianserin, Milnacipran, mirtazapine, moclobemide, naratriptan, olanzapine, ondansetron, oxetorone, paroxetine, pizotifen, risperidone, sertraline, sumatriptan, tianeptine, trimipramine, tropisetron, venlafaxine,viloxazine, zolmitriptan.
  • No consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00684736

CH Versailles - André Mignot Hospital
Le Chesnay, France, 78150
Sponsors and Collaborators
Versailles Hospital
Study Chair: Jean-Pierre Bédos, MD, PhD Versailles Hospital
Study Director: Odile Spreux-Varoquaux, PhD Versailles Hospital
Principal Investigator: Matthieu Henry-Lagarrigue, MD Versailles Hospital
  More Information

Responsible Party: Henry-Lagarrigue Matthieu/MD, Intensive Care Unit Identifier: NCT00684736     History of Changes
Other Study ID Numbers: TSK Sepsis
Study First Received: May 22, 2008
Last Updated: August 7, 2008

Keywords provided by Versailles Hospital:
septic shock

Additional relevant MeSH terms:
Shock, Septic
Pathologic Processes
Systemic Inflammatory Response Syndrome
Serotonin Receptor Agonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs processed this record on August 17, 2017